You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,006,281

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,006,281 protect, and when does it expire?

Patent 9,006,281 protects IBSRELA and is included in one NDA.

This patent has thirty-seven patent family members in twenty-one countries.

Summary for Patent: 9,006,281

Patent landscape, scope, and claims:

Title:	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Abstract:	The present disclosure is directed to compounds and methods for treating irritable bowel syndrome, chronic kidney disease and end stage renal disease by administering to a subject in need thereof a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure ##STR00001##
Inventor(s):	Bell; Noah (Fremont, CA), Carreras; Christopher (Fremont, CA), Charmot; Dominique (Fremont, CA), Jacobs; Jeffrey W (Fremont, CA), Leadbetter; Michael Robert (Fremont, CA), Navre; Marc (Fremont, CA)
Assignee:	Ardelyx, Inc. (Fremont, CA)
Application Number:	13/826,186
Patent Claim Types: see list of patent claims	Use;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 9,006,281

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET;ORAL	211801-001	Sep 12, 2019		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION BY ADMINISTERING TENAPANOR	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,006,281

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009334511	⤷ Subscribe
Brazil	PI0923861	⤷ Subscribe
Canada	2748607	⤷ Subscribe
China	102333759	⤷ Subscribe
China	103819403	⤷ Subscribe
Cyprus	1120451	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.